GlassScriptPhysician profile
Dean A Miller
NPI 1568416451
$1,004.62
in general payments reported to CMS, 2019-2025
19 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $113 · 2021: $81.03 · 2023: $22.23 · 2024: $27.10 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $285.30 | 2019-2025 | General - Therapies |
| Novo Nordisk INC | $279.57 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $59.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.40 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.70 | 2019 | |
| Viatris Specialty LLC | $32.06 | 2025 | Yupelri |
| Amarin Pharma, INC. | $28.93 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $26.51 | 2025 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $22.99 | 2019-2020 | |
| Allergan, INC. | $22.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.46 | 2019 | |
| Corcept Therapeutics | $15.36 | 2019 | |
| Astellas Pharma US INC | $14.92 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.81 | 2019 | |
| Pfizer INC. | $13.38 | 2019 | |
| Lilly USA, LLC | $13.27 | 2019 | |
| Intuitive Surgical, INC. | $4.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.